Big Pharma’s R&D spending flatlined in 2022: What it means for the industry
Bluebird Bio submits BLA for sickle cell disease gene therapy
Lilly sells low blood sugar rescue treatment to Amphastar for $500M-plus
Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
*please scroll down for all the latest news*
